132 related articles for article (PubMed ID: 10403528)
1. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
Dexter DT; Ward RJ; Florence A; Jenner P; Crichton RR
Biochem Pharmacol; 1999 Jul; 58(1):151-5. PubMed ID: 10403528
[TBL] [Abstract][Full Text] [Related]
2. An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators.
Longueville A; Crichton RR
Biochem Pharmacol; 1986 Nov; 35(21):3669-78. PubMed ID: 3778498
[TBL] [Abstract][Full Text] [Related]
3. Development of tridentate iron chelators: from desferrithiocin to ICL670.
Nick H; Acklin P; Lattmann R; Buehlmayer P; Hauffe S; Schupp J; Alberti D
Curr Med Chem; 2003 Jun; 10(12):1065-76. PubMed ID: 12678677
[TBL] [Abstract][Full Text] [Related]
4. Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic.
Baker E; Wong A; Peter H; Jacobs A
Br J Haematol; 1992 Jul; 81(3):424-31. PubMed ID: 1340769
[TBL] [Abstract][Full Text] [Related]
5. Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.
Kicic A; Chua AC; Baker E
Br J Pharmacol; 2002 Mar; 135(6):1393-402. PubMed ID: 11906952
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships among desazadesferrithiocin analogues.
Bergeron RJ; Wiegand J; McManis JS; Weimar WR; Huang G
Adv Exp Med Biol; 2002; 509():167-84. PubMed ID: 12572994
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
Bergeron RJ; Wiegand J; Dionis JB; Egli-Karmakka M; Frei J; Huxley-Tencer A; Peter HH
J Med Chem; 1991 Jul; 34(7):2072-8. PubMed ID: 2066978
[TBL] [Abstract][Full Text] [Related]
8. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.
Bergeron RJ; Wiegand J; Bharti N; McManis JS
J Med Chem; 2012 Aug; 55(16):7090-103. PubMed ID: 22889170
[TBL] [Abstract][Full Text] [Related]
9. Desferrithiocin and desferrioxamine B. Cellular pharmacology and storage iron mobilization.
Jin Y; Baquet A; Florence A; Crichton RR; Schneider YJ
Biochem Pharmacol; 1989 Oct; 38(19):3233-40. PubMed ID: 2818622
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo.
Waldmeier PC; Buchle AM; Steulet AF
Biochem Pharmacol; 1993 Jun; 45(12):2417-24. PubMed ID: 7687131
[TBL] [Abstract][Full Text] [Related]
11. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
Florence A; Ward RJ; Peters TJ; Crichton RR
Biochem Pharmacol; 1992 Sep; 44(6):1023-7. PubMed ID: 1417929
[TBL] [Abstract][Full Text] [Related]
12. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.
Kicic A; Chua AC; Baker E
Anticancer Drug Des; 2001; 16(4-5):195-207. PubMed ID: 12049478
[TBL] [Abstract][Full Text] [Related]
13. Scaffold Based Search on the Desferithiocin Archetype.
Shyam M; Dev A; Sinha BN; Jayaprakash V
Mini Rev Med Chem; 2019; 19(19):1564-1576. PubMed ID: 30827237
[TBL] [Abstract][Full Text] [Related]
14. The desferrithiocin pharmacophore.
Bergeron RJ; Liu CZ; McManis JS; Xia MX; Algee SE; Wiegand J
J Med Chem; 1994 May; 37(10):1411-7. PubMed ID: 8182699
[TBL] [Abstract][Full Text] [Related]
15. Desferrithiocin: a search for clinically effective iron chelators.
Bergeron RJ; Wiegand J; McManis JS; Bharti N
J Med Chem; 2014 Nov; 57(22):9259-91. PubMed ID: 25207964
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates.
Bergeron RJ; McManis JS; Bussenius J; Brittenham GM; Wiegand J
J Med Chem; 1999 Jul; 42(15):2881-6. PubMed ID: 10425097
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of a novel oral iron chelator: 1-(N-Acetyl-6-Aminohexyl)-3-Hydroxy-2-Methylpyridin-4-one.
Pangjit K; Banjerdpongchai R; Phisalaphong C; Fucharoen S; Xie YY; Lu ZD; Hider RC; Srichairatanakool S
J Pharm Pharmacol; 2015 May; 67(5):703-13. PubMed ID: 25627251
[TBL] [Abstract][Full Text] [Related]
18. Desferrithiocin analogues and nephrotoxicity.
Bergeron RJ; Wiegand J; McManis JS; Bharti N; Singh S
J Med Chem; 2008 Oct; 51(19):5993-6004. PubMed ID: 18788724
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of iron from (3,5,5-trimethylhexanoyl)ferrocene in rats. A dietary model for severe iron overload.
Nielsen P; Heinrich HC
Biochem Pharmacol; 1993 Jan; 45(2):385-91. PubMed ID: 8435091
[TBL] [Abstract][Full Text] [Related]
20. The design of orally active iron chelators.
Hider RC; Zhou T
Ann N Y Acad Sci; 2005; 1054():141-54. PubMed ID: 16339660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]